Ivarmacitinib in patients with active ankylosing spondylitis: subgroup analysis based on key baseline features from a phase II/III trial.
Xu B · 2026 · Clinical rheumatology
Reading the original? How to read a paper.
What this paper found
Ivarmacitinib, a JAK inhibitor in late-stage trials, outperformed placebo in active ankylosing spondylitis regardless of age, sex, weight, disease duration, CRP level, pain severity or whether people had already failed a biologic or another JAK drug, and the benefit held to 24 weeks. Another oral option may be coming, and this analysis says it works across the board rather than only in a favourable subgroup.
Why this is on the map
Adds a fourth JAK inhibitor to the thread, with subgroup data the existing tofacitinib and upadacitinib papers lack.
On the map under this thread
DOI: 10.1007/s10067-026-08305-6 · opens in a new tab. The full paper is on the publisher’s site, not here.
Related papers on the board
Papers sharing one or more threads with this one.
Current status and emerging trends in biological therapies for ankylosing spondylitis: a bibliometric analysis (2004–2024)
Medicine (LWW)
Bibliometric analysis of biological therapies for AS over 2004-2024. Confirms three pillars, TNF, IL-17, and JAK inhibitors, and a persistent inadequate response in a meaningful subset of patients across all three classes.
Advances in Axial Spondyloarthritis Treatment: The Role of Janus Kinase Inhibitors
International Journal of Rheumatic Diseases
Reviews the JAK inhibitor class, tofacitinib, upadacitinib, filgotinib, for axial spondyloarthritis. The 2025 CRA/SPARCC guidelines still place TNF inhibitors first-line, with JAK inhibitors recommended when TNFi is contraindicated or for patients with comorbid IBD.
Recent advances in biologic therapies for ankylosing spondylitis: a 2024 update
Allergologia et Immunopathologia
Comprehensive bDMARD review covering TNF, IL-17, and JAK inhibitor classes with their efficacy and safety profiles across the AS treatment landscape. Confirms a meaningful patient subset still has inadequate response across all three drug classes.
Efficacy of JAK inhibitors in immune-mediated inflammatory diseases: 2024 update of an international consensus statement
Annals of the Rheumatic Diseases
Systematic literature review of JAK inhibitor efficacy across immune-mediated inflammatory diseases. Effective broadly, but isoform selectivity (JAK1/2/3/TYK2) and the data on tapering or withdrawal remain unclear.